Collplant Biotechnologies Stock Fundamentals
| CLGN Stock | USD 5.41 0.01 0.19% |
Collplant Biotechnologies fundamentals help investors to digest information that contributes to Collplant Biotechnologies' financial success or failures. It also enables traders to predict the movement of Collplant Stock. The fundamental analysis module provides a way to measure Collplant Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Collplant Biotechnologies stock.
At this time, Collplant Biotechnologies' Total Other Income Expense Net is very stable compared to the past year. As of the 25th of April 2024, Total Revenue is likely to grow to about 11.5 M, while Depreciation And Amortization is likely to drop about 878.7 K. Collplant | Select Account or Indicator |
Collplant Biotechnologies Company Operating Margin Analysis
Collplant Biotechnologies' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Collplant Biotechnologies Operating Margin | (16.95) % |
Most of Collplant Biotechnologies' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Collplant Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Collplant Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Collplant Biotechnologies has an Operating Margin of -16.9498%. This is 51.68% lower than that of the Biotechnology sector and 84.88% lower than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Collplant Biotechnologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Collplant Biotechnologies's current stock value. Our valuation model uses many indicators to compare Collplant Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Collplant Biotechnologies competition to find correlations between indicators driving Collplant Biotechnologies's intrinsic value. More Info.Collplant Biotechnologies is rated third in return on equity category among related companies. It is rated second in return on asset category among related companies . At this time, Collplant Biotechnologies' Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Collplant Biotechnologies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Collplant Biotechnologies' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Collplant Biotechnologies' earnings, one of the primary drivers of an investment's value.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Collplant Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.64) % | ||||
| Operating Margin | (16.95) % | ||||
| Current Valuation | 38.44 M | ||||
| Shares Outstanding | 11.45 M | ||||
| Shares Owned By Insiders | 10.10 % | ||||
| Shares Owned By Institutions | 12.23 % | ||||
| Number Of Shares Shorted | 8.89 K | ||||
| Price To Earning | 92.60 X | ||||
| Price To Book | 2.12 X | ||||
| Price To Sales | 5.48 X | ||||
| Revenue | 10.96 M | ||||
| Gross Profit | 13.64 M | ||||
| EBITDA | (6.41 M) | ||||
| Net Income | (7.02 M) | ||||
| Cash And Equivalents | 36.29 M | ||||
| Cash Per Share | 3.27 X | ||||
| Total Debt | 3.16 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 16.21 X | ||||
| Book Value Per Share | 2.48 X | ||||
| Cash Flow From Operations | (2.76 M) | ||||
| Short Ratio | 1.29 X | ||||
| Earnings Per Share | (0.62) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 75 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 61.97 M | ||||
| Total Asset | 34.13 M | ||||
| Retained Earnings | (96.74 M) | ||||
| Working Capital | 24.77 M | ||||
| Current Asset | 17.03 M | ||||
| Current Liabilities | 6.37 M | ||||
| Net Asset | 34.13 M |
About Collplant Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Collplant Biotechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Collplant Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Collplant Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 28.8 K | 27.4 K | |
| Total Revenue | 11 M | 11.5 M | |
| Cost Of Revenue | 3.1 M | 3.2 M | |
| Stock Based Compensation To Revenue | 0.18 | 0.17 | |
| Sales General And Administrative To Revenue | 0.87 | 0.82 | |
| Research And Ddevelopement To Revenue | 0.96 | 0.91 | |
| Capex To Revenue | (0.09) | (0.09) | |
| Revenue Per Share | 0.96 | 0.52 | |
| Ebit Per Revenue | (0.69) | (0.72) |
Pair Trading with Collplant Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collplant Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving against Collplant Stock
| 0.61 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
| 0.55 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.54 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.5 | BMY | Bristol Myers Squibb Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Collplant Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collplant Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collplant Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collplant Biotechnologies to buy it.
The correlation of Collplant Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collplant Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collplant Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collplant Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Collplant Biotechnologies Piotroski F Score and Collplant Biotechnologies Altman Z Score analysis. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.Note that the Collplant Biotechnologies information on this page should be used as a complementary analysis to other Collplant Biotechnologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Collplant Stock analysis
When running Collplant Biotechnologies' price analysis, check to measure Collplant Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collplant Biotechnologies is operating at the current time. Most of Collplant Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Collplant Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collplant Biotechnologies' price. Additionally, you may evaluate how the addition of Collplant Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Collplant Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Revenue Per Share 0.962 | Quarterly Revenue Growth 4.155 | Return On Assets (0.13) | Return On Equity (0.23) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.